adaptive(US) | $7,000,000 | (Apr 23, 2025)
Tally(US) | $8,000,000 | (Apr 23, 2025)
Recce | $4,000,000 | (Apr 23, 2025) Certified by Founder
Lodge
Endogenex
start up
United States
- PLYMOUTH, MN
- 26/06/2024
- Series C
- $88,000,000
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression.
Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
- Industry Medical Equipment Manufacturing
- Website https://www.endogenex.com/
- LinkedIn https://www.linkedin.com/company/endogenexinc/
GreenFi | $17,000,000 | (Apr 23, 2025)
UbiQD, Inc. | $20,000,000 | (Apr 23, 2025)
Capably | $4,000,000 | (Apr 23, 2025)
Hopper Security | $7,600,000 | (Apr 23, 2025)
Arch Network | $13,000,000 | (Apr 23, 2025)